Revelle Launches Cellulite Reduction Device
Revelle Aesthetics, Inc—a Silicon Valley med-tech company focused on designing precision technologies that target the root cause of women’s aesthetic concerns—has announced the launch of Avéli™, a new cellulite device. According to company officials, Revelle’s mission is to develop smart aesthetic solutions that deliver meaningful results for women and reliable outcomes for practitioners.
The company recently introduced Avéli—a U.S. FDA-cleared device that temporarily reduces the appearance of cellulite on the buttocks and thighs in a one-time procedure—at The Aesthetic Society’s annual plastic surgery conference.
“Revelle was born out of ExploraMed, a Silicon Valley incubator known for engineering unique innovations in challenging-to-solve-for therapeutic areas,” says Caroline Van Hove, president and CEO of Revelle Aesthetics. “Revelle has spent the last few years in stealth mode focusing on deepening our understanding of the underlying anatomy and the challenges that need to be overcome when addressing cellulite. This extensive anatomical and clinical work enabled us to engineer a precision device that identifies and releases the culprit septa causing a cellulite depression and delivers visible and reproducible results that women and physicians want.”
“It has taken many years to understand the etiology of cellulite, in particular the structural cause—the fibrous septa—making it complicated to treat,” adds Michael Kaminer, MD, dermatologist and co-founder of SkinCare Physicians in Boston. “With the help of the engineering team at Revelle, we confirmed that the septa are a network of fibrous bands versus a singular, perpendicular band, and are significantly more complicated than we appreciated. Building on this knowledge, Avéli not only gives physicians control over identifying and releasing the complex structure of septa that are tethering the skin, but also allows verification of that release in real-time.”
Avéli is a one-time-use disposable device for cellulite designed to be used in a single in-office procedure using a Targeted, Verifiable Subcision™ method. During an advanced minimally invasive procedure with local anesthesia, a provider can treat both the buttocks and thighs for a variety of women across the spectrum of cellulite severity and complexity. Women can experience visible, meaningful results quickly after the procedure, with little-to-no downtime.
“It was exciting to see and hear the buzz around Avéli at The Aesthetic Meeting,” affirms Marina Del Rey, California-based plastic surgeon Grant Stevens, MD, FACS, founder and Medical Director of Marina Plastic Surgery, and past president of The Aesthetic Society. “Avéli is a novel and versatile device that I can offer as a standalone procedure or as part of a treatment plan with other nonsurgical or surgical body procedures.”
Published at Thu, 05 May 2022 19:17:32 +0000